Placebo and nocebo in the treatment of migraine: How much does real world effectiveness depend on contextual effects?
Cephalalgia · 2023-12 · 43 (12)
DOI: 10.1177/03331024231218392 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cephalalgia, online erschienen am 02.12.2023. Verfasst von Hauke Basedau und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Systems Neuroscience, University Medical Center Hamburg- Eppendorf, Hamburg, Germany. Hauptthemen laut MEDLINE: Nocebo Effect, Migraine Disorders. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 111 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Purpose
Treatments in medicine impact individuals beyond their intended effects, due to phenomena such as the placebo and nocebo effects. The placebo effect arises from the positive expectation of a treatment being beneficial, while the nocebo effect stems from the negative expectation of a treatment causing harm. Both in real-world practice and clinical trials, treatments can lead to outcomes unrelated to their intended mechanism of action, which we categorize as placebo and nocebo responses. These responses, combined with the inherent fluctuation in a condition's natural progression, regression to the mean, and random comorbidities, make up a significant part of the therapeutic experience. Particularly in pain management, placebo and nocebo effects play a substantial role. By addressing modifiable contextual factors such as patient expectations, lifestyle choices, and the therapeutic relationship, healthcare providers can enhance the effectiveness of migraine treatments, paving the way for a more comprehensive, individualized approach to patient care. We must also consider non-modifiable factors like personal experiences, beliefs, and information from social media and the internet.
Conclusion
This review offers a summary of our current understanding of the placebo and nocebo effects in migraine management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Systems Neuroscience, University Medical Center Hamburg- Eppendorf, Hamburg, Germany.
- Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
- Department of Neurology, State Special Servant Hospital of Mongolia, Ulaanbaatar, Mongolia.
- Department of Special Clinical Disciplines, International School of Medicine of International University of Kyrgyzstan, Bishkek, Kyrgyzstan.
- Department of Neurology and Algology, Neuropsychiatry Center, Neuroscience and Neurotechnology Center of Excellence (NÖROM), Gazi University, Ankara, Turkey.
- Department of Neurology, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine.
ORCID-Profile: Hauke Basedau, Raffaele Ornello, Elnura Eralieva, Dimos Mitsikostas, Francesca Puledda
Zitieren
APA
Basedau, H., Ornello, R., Matteis, E., Davaasuren, B., Kadyrova, B., Vuralli, D., Bozhenko, M., Azizova, I., Bitsadze, N., Eralieva, E., Ashina, M., Mitsikostas, D., & Puledda, F. (2023). Placebo and nocebo in the treatment of migraine: How much does real world effectiveness depend on contextual effects?. Cephalalgia, 43(12). https://doi.org/10.1177/03331024231218392
Vancouver
Basedau H, Ornello R, Matteis E, Davaasuren B, Kadyrova B, Vuralli D, et al. Placebo and nocebo in the treatment of migraine: How much does real world effectiveness depend on contextual effects?. Cephalalgia. 2023;43(12). doi:10.1177/03331024231218392
BibTeX
@article{Basedau2023,
author = {Basedau, Hauke and Ornello, Raffaele and Matteis, Eleonora De and Davaasuren, Bolortsetseg and Kadyrova, Begimai and Vuralli, Doga and Bozhenko, Myroslav and Azizova, Ilaha and Bitsadze, Natia and Eralieva, Elnura and Ashina, Messoud and Mitsikostas, Dimos and Puledda, Francesca},
title = {Placebo and nocebo in the treatment of migraine: How much does real world effectiveness depend on contextual effects?},
journal = {Cephalalgia},
year = {2023},
volume = {43},
number = {12},
doi = {10.1177/03331024231218392}
}
EUVIMED